Last reviewed · How we verify
Coenzyme Q
Coenzyme Q, marketed by Sherief Abd-Elsalam, is a commercially available drug with a key composition patent expiring in 2028. The drug's market position is bolstered by its patent protection, which provides a competitive advantage until expiry. The primary risk is the potential increase in competition post-2028, as generic versions may enter the market.
At a glance
| Generic name | Coenzyme Q |
|---|---|
| Sponsor | Sherief Abd-Elsalam |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Renoprotective Role of Vitamin C and Coenzyme Q10 in Nephrotoxicity (PHASE2, PHASE3)
- The Effect of Co-enzyme Q10 on the Clinical Outcome of Pediatric Patients With Systemic Lupus Erythematosus (PHASE2)
- Alpha Lipoic Acid Plus Coenzyme Q10 Versus Coenzyme Q10 Alone in Asthenozoospermia (NA)
- Comparing the Effects of Commercially Available Dietary Supplements on CoQ10 Concentrations (PHASE2, PHASE3)
- Effectiveness of Coenzyme Q10 and Probiotics in Periodontal Therapy During Pregnancy (NA)
- Coenzyme Q10 for Neuroprotection in Paclitaxel-Induced Neuropathy (PHASE2)
- North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC)
- Alii Supplement Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Coenzyme Q CI brief — competitive landscape report
- Coenzyme Q updates RSS · CI watch RSS
- Sherief Abd-Elsalam portfolio CI